**PRODUCT INFORMATION**

**EquiMAX®**
Ivermectin and praziquantel
Oral paste for horses
Veterinary Use Only

For the treatment of parasitic infections due to nematodes, cestodes, and gastric bots in horses and ponies.

**Benefits:**
- has been shown 100% effective against the most common species of tapeworm (A. perfoliata).
- Numerous studies have proven EquiMAX® safe for:
  - Foals four weeks of age and older.
  - Pregnant and lactating mares - No adverse effects on fertility.
  - Breeding stallions - Semen quality and reproductive hormone levels remained unaffected.
- A full dose contains enough active ingredients to treat horses weighing up to 1,320 lb.
- Easy-to-use-and-handle syringe/applicator for more accurate dosing.
- A smooth, quick-dissolving paste.
- Do not use in horses intended for human consumption.
- Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

**Packaging:**

<table>
<thead>
<tr>
<th>PRODUCT NO.</th>
<th>UNIT PACKAGE</th>
<th>OUTER CASE SIZE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1EQU027</td>
<td>6.42 g</td>
<td>6 x (12 x 6.42 g)</td>
</tr>
</tbody>
</table>

**Active Ingredients**
- 1.87% ivermectin
- 14.03% praziquantel

Other Available Brands
- 1.55% ivermectin
- 7.75% praziquantel
- 2.0% moxidectin
- 12.5% praziquantel

**Foals (Minimum Age)**
- 4 weeks
- 5 months
- 4 months

**Breeding Stallions**
- Yes
- No
- No

**Pregnant Mares**
- Yes
- No
- No

**Lactating Mares**
- Yes
- No
- No

**Syringe Dosage**
- Up to 600 kg
- Up to 600 kg
- Up to 575 kg

**Flavouring**
- Apple
- None

CAUTION: EquiMAX Oral Paste has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs may result. Reasonable care should be taken in the handling of sick or debilitated animals. Some horses have experienced reactions associated with swelling and itching shortly after treatment with various equine formulations of ivermectin. In most of these cases, the horses carried heavy infections of *Onchocerca* spp.; it is assumed that the reactions were the result of microfilariae dying in large numbers. Symptomatic treatment, administered by your veterinarian, may be advisable in such cases.

See reverse side for full Indications, Administration and Dosage.
EQUIMAX Oral Paste is a unique combination of ivermectin, a broad-spectrum antiparasitic and praziquantel, a compound active against tapeworms. Its convenience, broad-spectrum efficacy and wide safety margin make it an excellent antiparasitic product for horses.

ACTIVE INGREDIENTS: Ivermectin 1.87% w/w and praziquantel 14.03% w/w.

INTRODUCTION: EQUIMAX Oral Paste for horses is a member of the macrocyclic lactone class of endectocides caused by cutaneous larvae of EQUIMAX Oral Paste is also indicated as an aid in the clinical improvement of dermatoses in horses and ponies. Large strongyles: adult and arterial stages of Strongylus vulgaris, and adult stage of S. edentatus, S. equinus and Triodontophorus spp.


PRODUCT DESCRIPTION: EQUIMAX Oral Paste is a clean, white, homogeneous, ready-to-use paste contained in a disposable plastic syringe.

INDICATIONS: EQUIMAX Oral Paste is indicated for the treatment of the following parasitic infections in horses and ponies:

ADMINISTRATION: This syringe contains sufficient paste to treat one 600 kg horse at the recommended dose rate of 200 μg ivermectin/kg and 1500 μg praziquantel/kg body weight. Each weight marking on the syringe plungers delivers enough paste to treat 10 kg body weight.

ADDITIONAL INFORMATION: For the treatment of parasitic infections due to nematodes, cestodes, and gastric bots in horses and ponies.

WARNING: This drug must not be administered to horses that are to be slaughtered for meat or to the antibody-dependent immune effector mechanism. Praziquantel also causes alterations in the cestode’s metabolism, including decreases in glucose uptake, lactate release, glycogen content and ATP content.

SAFETY: The results of a tolerance study showed that foals, 2-4 weeks of age, treated at 10 times the recommended dosage of EQUIMAX Oral Paste, did not experience any clinically significant adverse effects. In a reproductive safety study conducted with breeding stallions, the data generated in regards to hematology, serum chemistry, seminal characteristics, reproductive behavior, physical/physiological characteristics, testicular size and reproductive hormone levels (LH and testosterone) indicate that EQUIMAX Oral Paste can be administered to stallions, at 3X the proposed dosage, given on three occasions at weekly intervals, without any biologically significant adverse effects on these parameters.

In a reproductive safety study, eleven mares were treated with a 3X dose of EQUIMAX Paste every two weeks throughout breeding, pregnancy and lactation, up until the foal was three months of age. Ten mares served as controls and were treated with the vehicle paste in a similar manner.

In the first few weeks of life, two foals born to the 3X treated mares had a higher incidence of transient ocular discharge and gastrointestinal disturbances (loose stools, diarrhea) and depression requiring medical intervention. However none of these observations were considered to be attributable to treatment.

SUGGESTED PARASITE CONTROL PROGRAM: All horses should be included in a regular parasite control program. Foals should be treated early in order to promote healthy growth and routine treatment repeated as appropriate. EQUIMAX Oral Paste effectively treats infections due to gastrointestinal nematodes, cestodes and bots of horses.

Regularity treatment with EQUIMAX Oral Paste will reduce the chances of colic caused by Anoplocephala perfoliata and vermiform arteritis caused by Strongylus vulgaris. The program should be designed to accommodate the needs of horses and their specific husbandry conditions. If there is a high risk of re-infection with P. equorum, foals should be treated at 8-10 week intervals. With its broad spectrum, EQUIMAX Oral Paste is well suited to be the major product in a parasite control program. Consult your veterinarian for parasitic control programs to meet your specific needs.

ENVIRONMENTAL SAFETY: Studies indicate that when ivermectin comes in contact with the soil, it readily and tightly binds to the soil and becomes inactive. Drug containers and any residual contents should be disposed safely (e.g., by burying or incinerating) as free ivermectin may adversely affect fish or certain waterborne organisms.

CAUTION: EQUIMAX Oral Paste has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs may result. Reasonable care should be taken in the handling of sick or debilitated animals. Some horses have experienced reactions associated with swelling and itching shortly after treatment with various equine formulations of ivermectin. In most of these cases, the horses carried heavy infections of Onchocerca spp.; it is assumed that the reactions were the result of microfilariae dying in large numbers. Symptomatic treatment, administered by your veterinarian, may be advisable in such cases.

PRESENTATION: EQUIMAX Oral Paste is available in disposable, plastic adjustable dosage syringes containing 6.42 g of paste.

STORAGE: Store below 30°C.

Distributed by: Bimeda-MTC Animal Health Inc., Cambridge ON N3C 2W4
Manufactured by: Virbac AH, Inc. 8920 Meacham Blvd. Fort Worth TX 76177 USA
® Registered trademark of Virbac S.A.

Bimeda-MTC Animal Health Inc. / Santé Animale Inc., 420 Beaverdale Road, Cambridge ON N3C 2W4
Phone (519) 654-8000 / Fax (519) 654-8001 / www.bimeda.com